Dyslipidaemia, Oxidative Stress And Arterial Wall Function In Non-Insulin Dependent Diabetes

A Double-Blind Randomised Placebo-Controlled Trial Of The Effects Of Fenofibrate And Coenzyme Q10 On Arterial Function In Type 2 Diabetic Subjects With Dyslipidaemia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611001150932

Enrollment

Registered

2011-11-02

Start date

1997-02-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To assess whether the combination of fenofibrate and coenzyme Q improves vascualr health in diabetes

Interventions

1.Fenofibrate 200mg/day orally 2.Coenzyme Q10 200mg/day orally 3.Fenofibrate 200mg/day plus Coezyme Q10 200mg/day orally 4.Placebo All for 12 weeks

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

Type 2 diabetes Dyslipidaemia (fasting serum triglycaeride >1.8mmol/L or HDL-cholesterol <1.0mmol/L, with total cholesterol <6.5mmol/L and total cholesterol-to-HDL-cholesterol ratio >4)

Exclusion criteria

Use of antioxidant or lipid-regulating therapy, insulin, angiotensin-converting enzyme inhibitors, calcium antagonists or aspirin Body mass index >40kg/m2 Uncontrolled hypertension (>160/90mmHg) Serum creatinine >150umol/L

Outcome results